8th June 2016, ASX Announcement
- Productive interaction with the US Food and Drug Administration (FDA)
- Protocol enhancement will strengthen the value of the Phase II trial
- Harmonising Australian and UK trial with US FDA increases potential global value
- Fits into broader US strategy of medical publications slated for 2H16 and US investor campaign in 2H16
Actinogen Medical Limited (Actinogen Medical, ASX: ACW) is pleased to announce productive progress with the US Food and Drug Administration (FDA) to enhance the safety profile of XanADu, the Phrase II trial of its lead Alzheimer’s drug candidate, Xanamem™.
Good progress has been made with the Actinogen Medical team towards securing final US FDA approval under an Investigational New Drug (IND) for the Phase II study.
To view the full announcement, please click on the button below.